Filed Pursuant to Rule 424(b)(5)
Registration No. 333-289262
The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and they are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
Subject to completion, dated September 22, 2026
Preliminary prospectus supplement
(To prospectus dated August 15, 2025)
Shares of Common Stock
Pre-funded Warrants to Purchase up to Shares of Common Stock

We are offering shares of our common stock, $0.0001 par value per share, in this offering, and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of common stock pursuant to this prospectus supplement and the accompanying prospectus. The purchase price of each pre-funded warrant equals the price per share at which shares of common stock are being sold to the public in this offering, minus $0.0001, and the exercise price of each pre-funded warrant equals $0.0001 per share. This prospectus supplement also relates to the offering of the shares of common stock issuable upon exercise of such pre-funded warrants.
The shares of our common stock (or pre-funded warrants) are immediately separable and will be issued separately.
We have engaged Konik Capital Partners, LLC, a division of T.R. Winston and Company, LLC (the underwriter or Konik), to act as underwriter in connection with this offering. We have agreed to issue warrants to the underwriter or its designees to purchase up to an aggregate number of shares of common stock equal to 7% of the aggregate number of shares of common stock sold in this offering at an exercise price equal to 250% of the public offering price per share to be sold in this offering (the underwriter warrants). The underwriter warrants will be exercisable at any time, and from time to time, in whole or in part, after issuance and expire one (1) year after the commencement of sales in this offering. The registration statement of which this prospectus is a part of registers the underwriter warrants and the shares of our common stock underlying the underwriter warrants. For additional information regarding the total compensation to be received by the underwriter, see “Underwriting” on page S-23 of this prospectus supplement.
Our common stock is listed on The Nasdaq Global Select Market under the symbol “BMEA.” On September 21, 2026, the last reported sale price of our common stock on The Nasdaq Global Select Market was $1.71 per share. There is no established public trading market for the pre-funded warrants, and we do not expect a market to develop. In addition, we do not intend to apply for a listing of the pre-funded warrants on the Nasdaq Global Select Market, any other national securities exchange or any other nationally recognized trading system.
Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page S-5 of this prospectus supplement, in the accompanying prospectus and in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus.
Neither the Securities and Exchange Commission (SEC) nor any other regulatory body has approved or disapproved of these securities or passed on the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.

